LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES;LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES;LFB- BIOTECHNOLOGIES
发明人:
申请号：
IL23010113
公开号：
IL230101A
申请日:
2013.12.23
申请国别(地区):
IL
年份:
2016
代理人:
摘要：
Use of an optimized chimeric humanized or human monoclonal antibody (MAb) to produce a composition for treating disease in which: (a) the number of antigen sites (antigenic density) is low or the antigens are poorly accessible to antibodies； or (b) the number of effector cells (EC) activated or recruited is low. Use of an optimized chimeric humanized or human monoclonal antibody (MAb) to produce a composition for treating disease in which: (a) the number of antigen sites (antigenic density) is low or the antigens are poorly accessible to antibodies； or (b) the number of effector cells (EC) activated or recruited is low. MAb has a glycan structure generally of the 'two-antennae' type, with short chains, low level of silylation of mannose and GlcNAc at the non-intercalated terminal points of attachment, low level of fucosylation and non-zero level of intermediate GlcNAc.
